Biobb

Why does fate mock me, wound me, condemn me, and trap me?

@mc_khristina lol

@CatCutiekitten So cute.

The bond between cat and parrot ❤️ pure love 💓

@CatCutiekitten lol

Kitten is talking a lot

@cutestscats lol

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial buff.ly/dJbHQV8 In the phase III APHINITY trial of HER2🧬 positive early #BreastCancer , adding pertuzumab to trastuzumab and chemotherapy🧪 improved invasive disease-free survival across biomarker-defined subgroups. The greatest benefit occurred in tumors with low HER2 FISH ratio and positive estrogen receptor status, while smaller gains were seen in other groups, particularly HER2 FISH-high/ER-negative disease. Findings were exploratory, consistent across molecular subtypes, and support future biomarker-guided treatment strategies in future clinical decision making. @ElisaAgostinett @serenadicosimo @aftimosp @noam_ponde @gabri_gentilee @eiger_daniel @matteolambe @LoiSher @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @Onco_Cifu88

Don't want to wake up.

Gn

ctDNA vs pCR in early breast cancer (HER2+/TNBC) Prospective PREDICT-DNA study shows: • ctDNA after neoadjuvant therapy does NOT reliably predict pCR (NPV 60%) • But it is a powerful prognostic marker Key signals: • Post-NAT ctDNA+ → ↑ recurrence risk (HR 8.9) • Post-surgery ctDNA+ → extreme risk (HR 128) • ctDNA− after surgery → 94% 5y IDFS 👉 ctDNA outperforms pCR for risk stratification 👉 Potential to guide escalation/de-escalation strategies @OncoAlert ascopubs.org/doi/10.1200/JC…

I hate my life so much.

I want to be young again.

@JoyfullCat lol

@LUX_FKD So cute.

子猫はようやく自分の居場所を見つけたかのように、道路を横切って彼女のもとに駆け寄り、ためらうことなく彼女の後をついてきた🐱彼女は子猫を飼うつもりはなかったのに彼はすでに自分の家を選んでいた🥹❤️

Abvx jumped 110 to 135 in Feb on antifibrotic data in the same TNBS model in which PDE4 has demonstrated better antifibrotic profile. Pali shockingly got sold on even better antifibrotic data and better CD potential. Ovid went up big on infantile spam indication addition which is likely to fail. Vigabatrin only works in ~25% patients with high relapse. May be works better with prednisolone combo. Hopefully Pali gets due credit now that geopolitics has appear to calm and many PRs lined up in next few days.

@didi_daisukedoi So beautiful! Love this piece.

夕日

🧬 APHINITY biomarker analysis: who benefits most from adjuvant pertuzumab? New data in JNCI refine the role of dual HER2 blockade in early breast cancer. 🔹 Phase III APHINITY sub-analysis (n=4,782 evaluable) 🔹 Pertuzumab + trastuzumab + chemo vs placebo Key findings: 🔸 Benefit observed across all subgroups 🔸 ⭐ Greatest benefit: ER+ / HER2 FISH-low (HR 0.70) 🔸 Smaller effect in HER2-high / ER− tumors 🔸 No clear differences by intrinsic subtype 💡 Clinical insight: Not all HER2+ tumors behave the same, ER status + HER2 expression level may refine patient selection for escalation. ⚠️ Exploratory → hypothesis-generating, needs prospective validation 🔗 academic.oup.com/jnci/advance-a… @ElisaAgostinett @JNCI_Now @myESMO @ASCO @kevinpunie @matteolambe @MartaPerachino @acampsmalea @FuenteApolo #BreastCancer #HER2 #PrecisionOncology #OncoTwitter #MedicalWatch

BREAKING: US oil prices fall nearly -10%, dropping below $101/barrel, after President Trump announces a 2-week ceasefire deal between the US and Iran, subject to the opening of the Strait of Hormuz. We now await comment from Iran.

@hiroyuki_life Amazing!

朝焼け

BREAKING: The S&P 500 erases all losses and turns green on the day as Pakistan asks President Trump to extend his 8 PM deadline by 2 weeks. Both sides have said they are reviewing the proposal.

$SNY still needs Dupi successor⤵️ Need: High Urgency: Moderately High Desperate: Not Yet Potential Targets 1st: $APGE best fit to defend Dupi w/ least friction 2nd: $NKTR novel MOA differentiated biologic hedge 3rd: $CRVS highest upside, cheapest oral option, most asymmetric 4th: $KYMR ambitious oral franchise rebuild, challenging full-company buyout "#lunsekimig eczema failure means Sanofi is no closer to having a guaranteed successor to its blockbuster dermatitis drug Dupixent as the patent cliff approaches" fiercebiotech.com/biotech/sanofi…